Loading market dashboard
BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF
XTENFinancial ServicesAMEXUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) for metastatic prostate cancer (NCT05997615). The Phase 1 trial is measuring the safety and efficacy of VIR-5500 monotherapy in late-line mCRPC, and of VIR-5500 in combination with an androgen receptor.
Park Avenue Securities LLC lowered its position in shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) by 19.8% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 151,919 shares of the company's stock after selling 37,510
